According to the Centers for Disease Control and Prevention, Hemophilia B is a genetic disorder caused by missing or defective Factor IX clotting protein. With the lack of this, the blood cannot clot properly to control bleeding like haemophilia A, it is also inherited and is caused by a spontaneous genetic mutation in one-third of the cases. Individuals with haemophilia B do not bleed faster than unaffected individuals, they bleed longer.
The main signs and symptoms of hemophilia are excessive bleeding and easy bruising. The child may suffer from recurrent nose bleeds, blood loss from small cuts, long-term bleeding in the mouth from bites, or after removal of a tooth, on-and-off bleeding from a cut or injury, bleeding within the skin or muscle and soft tissue that causes build-up of blood in the area. The diagnosis of hemophilia B is established in individuals with low factor IX clotting activity.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/hemophilia-b-market
The Hemophilia B market report also covers emerging drugs, current treatment practices, Hemophilia B market share of the individual therapies, current and forecasted Hemophilia B Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Hemophilia B treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Hemophilia B Market Key Facts
According to the World Federation of Hemophilia (WFH), the total number of cases around the World for Hemophilia B in 2018 was 34,289.
Centre for Disease Control and Prevention states Hemophilia occurs in about 1 of every 5,000 male births and Hemophilia A is about four times as common as Hemophilia B, and about half of those affected have a severe form. Hemophilia affects people from all racial and ethnic groups. Additionally, about 3 in 100 people with hemophilia B develop an inhibitor to the treatment product used to treat or prevent their bleeding episodes.
As per Santoro, Cristina, et al., 2018, the development of an inhibitor in Hemophilia B is a rare event that is., 1.5–3% of all patients but is associated with significant morbidity, related not only to the bleeding risk but also to the frequent occurrence of allergic reactions and nephrotic syndrome.
According to the National Hemophilia Foundation, there are three stages of hemophilia B: mild, moderate, and severe. In mild hemophilia the concentration of protein clotting factor FIX ranges between 6% and 49%. Similarly, moderate hemophilia ranges between 1% to up to 5%. In the case of severe hemophilia, the protein clotting factor in the blood is less than 1%.
Key Benefits of Hemophilia B Market Report
-
Hemophilia B market report provides an in-depth analysis of Hemophilia B Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
-
The Hemophilia B market report will help in developing business strategies by understanding the Hemophilia B Market trends & developments, key players and future market competition that will shape and drive the Hemophilia B market in the upcoming years.
-
The Hemophilia B market report covers Hemophilia B current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Hemophilia B market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Hemophilia B Market
The Hemophilia B market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Hemophilia B market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Hemophilia B market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Hemophilia B Epidemiology
The Hemophilia B epidemiology section covers insights about historical and current Hemophilia B patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Hemophilia B Drugs Uptake and Key Market Players
The Hemophilia B Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hemophilia B market or expected to get launched in the market during the study period. The analysis covers Hemophilia B market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of Hemophilia B market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, improvement in the half-life of products, raising awareness of the diseases, incremental healthcare spending across the world and expected the launch of emerging therapies during the forecast period. Companies across the globe are working towards the development of novel treatment therapies for Hemophilia B.
Hemophilia B Companies:
Sanofi
Alnylam Therapeutics
UniQure
Freeline Therapeutics
Pfizer
Novo Nordisk
Bioverativ Therapeutics (a Sanofi acquired company)
CSL Behring
And others
Hemophilia B Therapies Covered In The Report Include:
Rebinyn
Idelvion
Alprolix
FLT180a
And many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Hemophilia B Competitive Intelligence Analysis
4. Hemophilia B Market Overview at a Glance
5. Hemophilia B Disease Background and Overview
6. Hemophilia B Patient Journey
7. Hemophilia B Epidemiology and Patient Population
8. Hemophilia B Treatment Algorithm, Current Treatment, and Medical Practices
9. Hemophilia B Unmet Needs
10. Key Endpoints of Hemophilia B Treatment
11. Hemophilia B Marketed Products
12. Hemophilia B Emerging Therapies
13. Hemophilia B Seven Major Market Analysis
14. Attribute Analysis
15. Hemophilia B Market Outlook (7 major markets)
16. Hemophilia B Access and Reimbursement Overview
17. KOL Views on the Hemophilia B Market.
18. Hemophilia B Market Drivers
19. Hemophilia B Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Related Reports
Hemophilia B Epidemiology Forecast
DelveInsight's Hemophilia B - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Hemophilia B in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Hemophilia B Pipeline Insights
Hemophilia B Pipeline Insight, 2020 report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Hemophilia B market.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: +919650213330
Address:304 S. Jones Blvd. 2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
